316 related articles for article (PubMed ID: 33525370)
1. Outcomes of Patients with Pulmonary Large Cell Neuroendocrine Carcinoma in I-IV Stage.
Lowczak A; Kolasinska-Cwikla A; Osowiecka K; Glinka L; Palucki J; Rzepko R; Doboszynska A; Cwikla JB
Medicina (Kaunas); 2021 Jan; 57(2):. PubMed ID: 33525370
[No Abstract] [Full Text] [Related]
2. Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
Zhang JT; Li Y; Yan LX; Zhu ZF; Dong XR; Chu Q; Wu L; Zhang HM; Xu CW; Lin G; Yu ZY; Hu J; Zhu B; Wang HJ; Yang F; Song ZB; Han ZB; Li MX; Lin J; Wu YL; Wang JL; Zhong WZ
Lung Cancer; 2020 Jan; 139():118-123. PubMed ID: 31775086
[TBL] [Abstract][Full Text] [Related]
3. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy.
Saji H; Tsuboi M; Matsubayashi J; Miyajima K; Shimada Y; Imai K; Kato Y; Usuda J; Kajiwara N; Uchida O; Ohira T; Hirano T; Mukai K; Kato H; Ikeda N
Anticancer Drugs; 2010 Jan; 21(1):89-93. PubMed ID: 19770636
[TBL] [Abstract][Full Text] [Related]
4. Effect of chemotherapy in patients with resected small-cell or large-cell neuroendocrine carcinoma.
Abedallaa N; Tremblay L; Baey C; Fabre D; Planchard D; Pignon JP; Guigay J; Pechoux CL; Soria JC; de Montpreville VT; Besse B
J Thorac Oncol; 2012 Jul; 7(7):1179-83. PubMed ID: 22617247
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
Derks JL; van Suylen RJ; Thunnissen E; den Bakker MA; Groen HJ; Smit EF; Damhuis RA; van den Broek EC; Speel EM; Dingemans AC;
Eur Respir J; 2017 Jun; 49(6):. PubMed ID: 28572122
[TBL] [Abstract][Full Text] [Related]
6. Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.
Naidoo J; Santos-Zabala ML; Iyriboz T; Woo KM; Sima CS; Fiore JJ; Kris MG; Riely GJ; Lito P; Iqbal A; Veach S; Smith-Marrone S; Sarkaria IS; Krug LM; Rudin CM; Travis WD; Rekhtman N; Pietanza MC
Clin Lung Cancer; 2016 Sep; 17(5):e121-e129. PubMed ID: 26898325
[TBL] [Abstract][Full Text] [Related]
7. Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study.
Le Treut J; Sault MC; Lena H; Souquet PJ; Vergnenegre A; Le Caer H; Berard H; Boffa S; Monnet I; Damotte D; Chouaid C
Ann Oncol; 2013 Jun; 24(6):1548-52. PubMed ID: 23406729
[TBL] [Abstract][Full Text] [Related]
8. Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancer.
Huang L; Feng Y; Xie T; Zhu H; Tang L; Shi Y
BMC Cancer; 2023 Apr; 23(1):312. PubMed ID: 37020179
[TBL] [Abstract][Full Text] [Related]
9. A clinicopathological study of peripheral, small-sized high-grade neuroendocrine tumours of the lung: differences between small-cell lung carcinoma and large-cell neuroendocrine carcinoma.
Isaka M; Nakagawa K; Ohde Y; Okumura T; Watanabe R; Ito I; Nakajima T; Kondo H
Eur J Cardiothorac Surg; 2012 Apr; 41(4):841-6. PubMed ID: 22219429
[TBL] [Abstract][Full Text] [Related]
10. The Role of Systemic Therapy in the Management of Stage I Large Cell Neuroendocrine Carcinoma of the Lung.
Kujtan L; Muthukumar V; Kennedy KF; Davis JR; Masood A; Subramanian J
J Thorac Oncol; 2018 May; 13(5):707-714. PubMed ID: 29391287
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study.
Niho S; Kenmotsu H; Sekine I; Ishii G; Ishikawa Y; Noguchi M; Oshita F; Watanabe S; Nakajima R; Tada H; Nagai K
J Thorac Oncol; 2013 Jul; 8(7):980-4. PubMed ID: 23774385
[TBL] [Abstract][Full Text] [Related]
12. DLL3 expression is a predictive marker of sensitivity to adjuvant chemotherapy for pulmonary LCNEC.
Ogawa H; Sakai Y; Nishio W; Fujibayashi Y; Nishikubo M; Nishioka Y; Tane S; Kitamura Y; Sudo T; Sakuma T; Yoshimura M
Thorac Cancer; 2020 Sep; 11(9):2561-2569. PubMed ID: 32691982
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?
Sun JM; Ahn MJ; Ahn JS; Um SW; Kim H; Kim HK; Choi YS; Han J; Kim J; Kwon OJ; Shim YM; Park K
Lung Cancer; 2012 Aug; 77(2):365-70. PubMed ID: 22579297
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of Patients with Clinical Stage I-IIIA Large-Cell Neuroendocrine Lung Cancer Treated with Resection.
Lowczak A; Kolasinska-Cwikla A; Ćwikła JB; Osowiecka K; Palucki J; Rzepko R; Glinka L; Doboszyńska A
J Clin Med; 2020 May; 9(5):. PubMed ID: 32392725
[TBL] [Abstract][Full Text] [Related]
15. Platinum Doublet plus Atezolizumab as First-line Treatment in Metastatic Large Cell Neuroendocrine Carcinoma: A Single Institution Experience.
Vrontis K; Economidou SC; Fotopoulos G
Cancer Invest; 2022 Feb; 40(2):124-131. PubMed ID: 34601985
[TBL] [Abstract][Full Text] [Related]
16. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
Zhuo M; Guan Y; Yang X; Hong L; Wang Y; Li Z; Chen R; Abbas HA; Chang L; Gong Y; Wu N; Zhong J; Chen W; Chen H; Dong Z; Zhu X; Li J; Wang Y; An T; Wu M; Wang Z; Wang J; Roarty EB; Rinsurongkawong W; Lewis J; Roth JA; Swisher SG; Lee JJ; Heymach JV; Wistuba II; Kalhor N; Yang L; Yi X; Futreal PA; Glisson BS; Xia X; Zhang J; Zhao J
Clin Cancer Res; 2020 Feb; 26(4):892-901. PubMed ID: 31694833
[TBL] [Abstract][Full Text] [Related]
17. Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung.
Rossi G; Cavazza A; Marchioni A; Longo L; Migaldi M; Sartori G; Bigiani N; Schirosi L; Casali C; Morandi U; Facciolongo N; Maiorana A; Bavieri M; Fabbri LM; Brambilla E
J Clin Oncol; 2005 Dec; 23(34):8774-85. PubMed ID: 16314638
[TBL] [Abstract][Full Text] [Related]
18. Clinical features of large cell neuroendocrine carcinoma: a population-based overview.
Derks JL; Hendriks LE; Buikhuisen WA; Groen HJ; Thunnissen E; van Suylen RJ; Houben R; Damhuis RA; Speel EJ; Dingemans AM
Eur Respir J; 2016 Feb; 47(2):615-24. PubMed ID: 26541538
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma.
Iida Y; Wakuda K; Kenmotsu H; Doshita K; Kodama H; Nishioka N; Miyawaki E; Miyawaki T; Mamesaya N; Kobayashi H; Omori S; Ko R; Ono A; Naito T; Murakami H; Sugino T; Gon Y; Takahashi T
Sci Rep; 2024 Apr; 14(1):7641. PubMed ID: 38561461
[TBL] [Abstract][Full Text] [Related]
20. Pathological features, clinical presentations and prognostic factors of ovarian large cell neuroendocrine carcinoma: a case report and review of published literature.
Yang X; Chen J; Dong R
J Ovarian Res; 2019 Jul; 12(1):69. PubMed ID: 31345245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]